Our findings bridge a critical knowledge gap by reporting the first case of concurrent tislelizumab-induced DKA and hypothyroidism in HER2-positive EAC, particularly notable for its unprecedented 11-month delayed onset after therapy cessation—a phenomenon previously undocumented in this malignancy. This evidence concerns the gene ERBB2 and hypothyroidism.